- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Here's a summary of Rubicon Research Limited's investor presentation:
**Business Performance:** Q1 FY27 saw strong YoY revenue growth of 51.6% to ₹5,343 million. EBITDA and PAT also surged by 64.6% and 95.8% respectively. This growth was broad-based, with USD revenue reaching $55 million, up 32% YoY.
**Growth Drivers or Strategy:** Rubicon continues to focus on specialty and differentiated products, which are driving stable pricing and contributing significantly to gross profit. The company is also expanding its manufacturing footprint with new facilities, including its first US manufacturing site in New Jersey.
**Recent Developments:** A key development is the acquisition of a USFDA-approved manufacturing facility in East Brunswick, New Jersey, for $2.9 million. This provides a strategic US manufacturing base. The Pithampur facility has also received USFDA approval for commercial operations ramp-up.
**Key Financial Metrics:** Revenue from operations grew 51.6% YoY in Q1 FY27. PAT increased by 95.8% YoY. Operating EBITDA margin improved to 24.2% from 23.1% sequentially, and the company now expects FY27 operating EBITDA margins to be at least 23%.
**Management Commentary / Outlook:** The company foresees strong revenue visibility in the coming quarters. Strategic pricing measures and capacity optimization are in place to support expected revenue traction. Rubicon is also investing in R&D, with a projected spend of ₹5,000 million+ over FY26-FY28, providing strong future revenue visibility.